Citation: Zhen Li, Peilu Song, Yujie Liu, Xiuyun Sun, Xin Zhai, Yu Rao. Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands[J]. Chinese Chemical Letters, ;2026, 37(3): 111033. doi: 10.1016/j.cclet.2025.111033 shu

Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands

Zhen Li ^{a, 1} ,
Peilu Song ^{b, 1} ,
Yujie Liu ^b ,
Xiuyun Sun ^{c, *,} ,
Xin Zhai ^{a, *,} ,
Yu Rao ^{b, c, *,}

a.
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
b.
State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, Beijing 100084, China
c.
Changping Laboratory, Beijing 102206, China

sunxiuyun622@126.com

zhaixin_syphu@126.com

yrao@tsinghua.edu.cn

Received Date: 24 October 2024
Revised Date: 28 February 2025
Accepted Date: 4 March 2025
Available Online: 4 March 2025

Figures(5)

Interleukin-1 receptor-associated kinase 4 (IRAK4), a key target with both enzymatic and non-enzymatic functions, plays a pivotal role in autoimmune diseases. Previous studies have demonstrated that proteolysis-targeting chimera (PROTAC) molecules targeting IRAK4 can effectively eliminate both its enzymatic and non-enzymatic functions, showing promising therapeutic potential. However, the development of highly potent, synthetically accessible IRAK4-targeting degraders remains a challenge. In this work, through three rounds of PROTAC library construction, screening, and optimization, we successfully identified a representative compound, LZ-07, which proved to be a highly potent degrader with a half-maximal degradation concentration (DC₅₀) value of 1.14 nmol/L. Notably, compared with KT-474, LZ-07 demonstrated comparable degradation activity and superior inhibition of cytokine production, while featuring a simpler synthetic route with optimized IRAK4 and cereblon (CRBN) ligands. LZ-07-induced degradation of IRAK4 led to marked suppression of key cytokines, including interleukin-6 (IL-6), IL-1β, tumor necrosis factor alpha (TNF-α), and IL-10. This study presents LZ-07 as a novel, highly efficient, and synthetically straightforward IRAK4-targeting degrader, offering a promising tool compound for the study of the potential treatment of autoimmune diseases.
- IRAK4-targeting degraders,
- Simplified CRBN ligands,
- Non-enzymatic functions,
- Inflammatory cytokines inhibition,
- Autoimmune diseases
1. [1]
  S. Flannery, A.G. Bowie, Biochem. Pharmacol. 80 (2010) 1981–1991. doi: 10.1016/j.bcp.2010.06.020
2. [2]
  K. Kobayashi, L.D. Hernandez, J.E. Galán, et al., Cell 110 (2002) 191–202. doi: 10.1016/S0092-8674(02)00827-9
3. [3]
  T. Kawai, S. Akira, Nat. Immunol. 11 (2010) 373–384. doi: 10.1038/ni.1863
4. [4]
  P.G. Motshwene, M.C. Moncrieffe, J.G. Grossmann, et al., J. Biol. Chem. 284 (2009) 25404–25411. doi: 10.1074/jbc.M109.022392
5. [5]
  A.P. West, A.A. Koblansky, S. Ghosh, Annu. Rev. Cell Dev. Biol. 22 (2006) 409–437. doi: 10.1146/annurev.cellbio.21.122303.115827
6. [6]
  K. Takeda, S. Akira, Semin. Immunol. 16 (2004) 3–9. doi: 10.1016/j.smim.2003.10.003
7. [7]
  S. De, F. Karim, E. Kiessu, et al., J. Biol. Chem. 293 (2018) 15208–15220. doi: 10.1074/jbc.ra118.003831
8. [8]
  K. Yang, A. Puel, S. Zhang, et al., Immunity 23 (2005) 465–478. doi: 10.1016/j.immuni.2005.09.016
9. [9]
  C.L. Ku, H. von Bernuth, C. Picard, et al., J. Exp. Med. 204 (2007) 2407–2422. doi: 10.1084/jem.20070628
10. [10]
  J.J. O’Shea, S.M. Holland, L.M. Staudt, N. Engl. J. Med. 368 (2013) 161–170. doi: 10.1056/NEJMra1202117
11. [11]
  S. Lavazais, M. Jargosch, S. Dupont, et al., Sci. Transl. Med. 15 (2023) eabj3289. doi: 10.1126/scitranslmed.abj3289
12. [12]
  S. Umar, K. Palasiewicz, K. Van Raemdonck, et al., Cell. Mol. Immunol. 18 (2021) 2199–2210. doi: 10.1038/s41423-020-0433-8
13. [13]
  G. Otto, Nat. Rev. Rheumatol. 17 (2021) 646. doi: 10.1038/s41584-021-00699-8
14. [14]
  S.I. Danto, N. Shojaee, R.S.P. Singh, et al., Arthritis Res. Ther. 21 (2019) 269. doi: 10.1186/s13075-019-2008-6
15. [15]
  Y. Feng, C. Chen, A. Shao, et al., Acta Pharm. Sin. B 14 (2024) 5091–5105. doi: 10.1016/j.apsb.2024.09.008
16. [16]
  M. He, C. Cao, Z. Ni, et al., Signal. Transduct. Target. Ther. 7 (2022) 181. doi: 10.1038/s41392-022-00999-9
17. [17]
  M. Békés, D.R. Langley, C.M. Crews, Nat. Rev. Drug Discov. 21 (2022) 181–200. doi: 10.1038/s41573-021-00371-6
18. [18]
  A. Chen, Y. Zhong, Y. Liu, et al., Chin. Chem. Lett. 34 (2023) 107923. doi: 10.1016/j.cclet.2022.107923
19. [19]
  Z. Kang, S. Li, Y. Li, et al., Chin. Chem. Lett. 36 (2025) 110447. doi: 10.1016/j.cclet.2024.110447
20. [20]
  J. Nunes, G.A. McGonagle, J. Eden, et al., ACS Med. Chem. Lett. 10 (2019) 1081–1085. doi: 10.1021/acsmedchemlett.9b00219
21. [21]
  L. Ackerman, G. Acloque, S. Bacchelli, et al., Nat. Med. 29 (2023) 3127–3136. doi: 10.1038/s41591-023-02635-7
22. [22]
  J. Krönke, N.D. Udeshi, A. Narla, et al., Science 343 (2014) 301–305. doi: 10.1126/science.1244851
23. [23]
  J. Krönke, S.N. Hurst, B.L. Ebert, Oncoimmunology 3 (2014) e941742. doi: 10.4161/21624011.2014.941742
24. [24]
  M. Costacurta, J. He, P.E. Thompson, J. Shortt. J. Pers. Med. 11 (2021) 1185. doi: 10.3390/jpm11111185
25. [25]
  C. Steinebach, A. Bricelj, A. Murgai, et al., J. Med. Chem. 66 (2023) 14513–14543. doi: 10.1021/acs.jmedchem.3c00851
26. [26]
  S.L. Degorce, A. Aagaard, R. Anjum, et al., Bioorg. Med. Chem. 28 (2020) 115815. doi: 10.1016/j.bmc.2020.115815
27. [27]
  G.F. Smith, M.D. Altman, B. Andresen, et al., Bioorg. Med. Chem. Lett. 27 (2017) 2721–2726. doi: 10.1016/j.bmcl.2017.04.050
28. [28]
  S. Ichikawa, H.A. Flaxman, W. Xu, et al., Nature 610 (2022) 775–782. doi: 10.1038/s41586-022-05333-5
29. [29]
  M.W.D. Perry, R. Abdulai, M. Mogemark, et al., J. Med. Chem. 62 (2019) 4783–4814. doi: 10.1021/acs.jmedchem.8b01298
1. [1]
  Zimo Yang , Yan Tong , Yongbo Liu , Qianlong Liu , Zhihao Ni , Yuna He , Yu Rao . Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chinese Chemical Letters, 2024, 35(11): 109577-. doi: 10.1016/j.cclet.2024.109577
2. [2]
  Yutong Chen , Shuting Guo , Mingrui Fan , Songlin Yang , Qiuxia Lin , Jiafeng Zou , Junyuan Xu , Tongtong Zheng , Kangtai He , Feng Gao , Yanzuo Chen . Exosome-liposome hybrid system with antioxidant and anti-inflammatory activities targeting glial cells for the treatment of central nervous system diseases. Chinese Chemical Letters, 2026, 37(9): 112027-. doi: 10.1016/j.cclet.2025.112027
3. [3]
  Feifei Wang , Hang Yao , Xinyue Wu , Yijian Tang , Yang Bai , Hui Chong , Huan Pang . Metal–organic framework and its composites modulate macrophage polarization in the treatment of inflammatory diseases. Chinese Chemical Letters, 2024, 35(5): 108821-. doi: 10.1016/j.cclet.2023.108821
4. [4]
  Xinying Wang , Yuhang Fan , Xiyao Dong , Han Wu , Qingxiang Guan . Perspective and application advancements of chemically modified exosomes as novel tools for precise targeting in brain diseases: A strategic appraisal. Chinese Chemical Letters, 2026, 37(10): 112152-. doi: 10.1016/j.cclet.2025.112152
5. [5]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
6. [6]
  Weijian Zhang , Xianyu Deng , Liying Wang , Jian Wang , Xiuting Guo , Lianggui Huang , Xinyi Wang , Jun Wu , Linjia Jiang . Poly(ferulic acid) nanocarrier enhances chemotherapy sensitivity of acute myeloid leukemia by selectively targeting inflammatory macrophages. Chinese Chemical Letters, 2024, 35(9): 109422-. doi: 10.1016/j.cclet.2023.109422
7. [7]
  Rongrong Zheng , Zuxiao Chen , Qiuyuan Li , Ni Yang , Wenjun Zhang , Chuyu Huang , Linping Zhao , Xin Chen , Hong Cheng , Shiying Li . Endoplasmic reticulum targeting photodynamic oxidizer to boost anti-tumor immunity by intensifying immunogenic cell death in conjunction with IDO1 inhibition. Chinese Chemical Letters, 2025, 36(12): 110865-. doi: 10.1016/j.cclet.2025.110865
8. [8]
  Zhaoyong Kang , Shen Li , Yan Li , Jingfeng Song , Yangrui Peng , Yihua Chen . Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024). Chinese Chemical Letters, 2025, 36(7): 110447-. doi: 10.1016/j.cclet.2024.110447
9. [9]
  Dandan Wang , Xiaoyu Ma , Yijin Zhao , Wenting Zou , Hua Wang , Yang Gao , Shimeng Wan , Jian Ni , Lilan Xin , Hai-Bing Zhou , Hongbing Cai , Chune Dong . The discovery of acyl thiourea derivatives as potent hydrophobic tagging degraders targeting SIRT2 for the treatment of ovarian cancer. Chinese Chemical Letters, 2026, 37(4): 111143-. doi: 10.1016/j.cclet.2025.111143
10. [10]
  Yifan Feng , Chengjuan Chen , Anqi Shao , Qingyang Zhang , Lan Sun , Hai-Yu Hu , Tiantai Zhang . Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs. Chinese Chemical Letters, 2025, 36(12): 110963-. doi: 10.1016/j.cclet.2025.110963
11. [11]
  Jing Guo , Zhi-Guo Lu , Rui-Chen Zhao , Bao-Ku Li , Xin Zhang . Nucleic acid therapy for metabolic-related diseases. Chinese Chemical Letters, 2025, 36(3): 109875-. doi: 10.1016/j.cclet.2024.109875
12. [12]
  Dayang Xie , Qiannan Cao , Huapan Fang , Yanhui Li , Huayu Tian . Applications and challenges of biomedical polymer materials in pulmonary diseases. Chinese Chemical Letters, 2026, 37(2): 111032-. doi: 10.1016/j.cclet.2025.111032
13. [13]
  Xiaodan Liang , Tong Tong , Caihong Xian , Jiyuan Du , Biying Tan , Liying Wang , Jingyi Hou , Jun Wu . Metal-based biomaterials for treating bone diseases. Chinese Chemical Letters, 2026, 37(4): 111140-. doi: 10.1016/j.cclet.2025.111140
14. [14]
  Jiangmin Zhu , Qimei Tan , Shiying Fan , Yalin Li , Ling Zhu , Lihong Hong , Yuxia Wang , Chuzhen Zhang , Chen Chen , Lingyi Kong , Jianguang Luo . PROTAC degraders of FSP1 act as potent GPX4 sensitizers to induce ferroptosis for hepatoma treatment. Chinese Chemical Letters, 2026, 37(5): 111285-. doi: 10.1016/j.cclet.2025.111285
15. [15]
  Yuhao Jin , Zheng Zhou , Haixiang Han . Revisit the classical [Fe4S4(SR)4]2– molecular clusters: The steric effects of ligands and their structural transformations. Chinese Journal of Structural Chemistry, 2025, 44(9): 100660-100660. doi: 10.1016/j.cjsc.2025.100660
16. [16]
  Lian Jin , Juan Zhang , Libo Nie , Yan Deng , Ghulam Jilany Khana , Nongyue He . Chitosan nanoparticles act as promising carriers of microRNAs to brain cells in neurodegenerative diseases. Chinese Chemical Letters, 2025, 36(10): 110774-. doi: 10.1016/j.cclet.2024.110774
17. [17]
  Mengdie Li , Shundong Cai , Hongjin Li , Yuhang Cheng , Jinfa Ye , Lang Ke , Yun Han , Min Su , Gang Liu , Chengchao Chu . Nanotherapeutics for ocular posterior segment diseases therapy: Towards its advances and challenges. Chinese Chemical Letters, 2026, 37(5): 111392-. doi: 10.1016/j.cclet.2025.111392
18. [18]
  Jiahao Huang , Yongfeng Lan , Lifa Chen , Xiaoxuan Guan , Rong Liang , Jiatong Liang , Ming Gao , Jialiang Gan , Yun Guo , Sen Zhang . Living therapeutics: Colorectal related diseases precision therapy with engineered organisms. Chinese Chemical Letters, 2026, 37(6): 112151-. doi: 10.1016/j.cclet.2025.112151
19. [19]
  Kaiqing Zhang , Yue Zhou , Guanlin Wang , Bing Zhu , Ziyu Zhao , Xi Kong , Yihong Gao , Xin Pan , Zhengwei Huang , Chuanbin Wu , Xuejuan Zhang . Pulmonary mRNA delivery systems for the treatment of respiratory diseases: Current advances and challenges. Chinese Chemical Letters, 2026, 37(8): 111887-. doi: 10.1016/j.cclet.2025.111887
20. [20]
  Yuke Ji , Jia Liang , Xiangqing Hei , Lu Chen , Shudong Yu , Dong Fang , Hui Tan , Shaochong Zhang . Nanomaterial-based drug delivery systems for ocular diseases: A review. Chinese Chemical Letters, 2026, 37(9): 112062-. doi: 10.1016/j.cclet.2025.112062

Get Citation

PDF

XML

Metrics

PDF Downloads(8)
Abstract views(973)
HTML views(58)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142